AbCellera Biologics (ABCL) investor relations material

Strategic platform evolution and technology investments

• Over 13 years, significant investments built an integrated antibody-based drug discovery and manufacturing platform, enabling pursuit of challenging therapeutic targets and internal program development.

• Experience from over 100 drug discovery programs has led to a pipeline with the first internal drug advancing to phase II, positioning the company as a mid to late-stage biotech.

Pipeline prioritization and development criteria

• Pipeline programs are selected based on de-risked science, unmet medical need, commercial opportunity, competitive advantage, and a clear, affordable development path.

• Lead program ABCL635, a non-hormonal treatment for hot flashes, began phase II at the end of last year with a readout expected in Q3; ABCL575 is in phase I with a Q4 readout.

• Two additional programs are in IND-enabling stages, with about 20 more in earlier development.

Lead asset ABCL635: clinical profile and market potential

• ABCL635 targets vasomotor symptoms in menopause, aiming for efficacy comparable to recent small molecule entrants but with improved safety and monthly auto-injectable convenience.

• Phase I data showed no safety concerns and pharmacodynamics support monthly dosing; phase II will determine efficacy.

• Potential exists to expand ABCL635 to treat hot flashes from hormone-suppressing cancer therapies in both women and men.